Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein (a)

P N Durrington1

  • 1University of Manchester, UK.

Bailliere'S Clinical Endocrinology and Metabolism
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Lipoprotein (a) [Lp(a)] is similar to LDL but has unique apolipoprotein (a) [apo(a)]. Genetic variations in apo(a) length influence Lp(a) levels and are linked to atherosclerosis risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national hospital records.

Atherosclerosis·2025
Same author

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.

Atherosclerosis·2018
Same author

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

European journal of preventive cardiology·2011
Same author

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).

Diabetic medicine : a journal of the British Diabetic Association·2010
Same author

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.

Atherosclerosis·2010
Same author

Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations.

Atherosclerosis·2009
Same journal

Phytoestrogen content in foods.

Bailliere's clinical endocrinology and metabolism·1999
Same journal

Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data.

Bailliere's clinical endocrinology and metabolism·1999
Same journal

Experimental studies on lignans and cancer.

Bailliere's clinical endocrinology and metabolism·1999
Same journal

Reproductive actions of phytoestrogens.

Bailliere's clinical endocrinology and metabolism·1999
Same journal

Phytoestrogens and inhibition of angiogenesis.

Bailliere's clinical endocrinology and metabolism·1999
Same journal

Phytoestrogens and diseases of the prostate gland.

Bailliere's clinical endocrinology and metabolism·1999
See all related articles

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiovascular Medicine

Background:

  • Lipoprotein (a) [Lp(a)] resembles low-density lipoprotein (LDL) but includes apolipoprotein (a) [apo(a)].
  • Apo(a) belongs to the plasminogen gene superfamily and possesses a non-activated protease domain, differing significantly from plasminogen.
  • Genetic variations in apo(a) length lead to diverse molecular masses and serum Lp(a) concentrations, with lower levels common in Europid populations.

Purpose of the Study:

  • To investigate the role of Lipoprotein (a) [Lp(a)] in atherogenesis and thrombosis.
  • To understand the physiological functions of Lp(a), including potential roles in hemostasis and wound healing.
  • To explore the association between elevated Lp(a) levels and diseases like renal disease and atherosclerosis.

Main Methods:

Related Experiment Videos

  • Analysis of genetic variation in apolipoprotein (a) [apo(a)] length.
  • Epidemiological studies examining the association between serum Lp(a) levels and cardiovascular risk factors.
  • Comparison of Lp(a) levels in various disease states, including renal disease and atherosclerosis.

Main Results:

  • Inherited differences in apo(a) molecular mass are the primary drivers of wide-ranging serum Lp(a) concentrations.
  • Epidemiological data strongly suggest Lp(a) is an independent risk factor for atherosclerosis, especially in individuals with high LDL levels.
  • Elevated Lp(a) levels, beyond genetically determined ones, are observed in conditions like renal disease and potentially atherosclerosis.

Conclusions:

  • Genetic variation in apo(a) significantly impacts serum Lp(a) levels and influences cardiovascular risk.
  • Lp(a) plays a potential role in hemostasis and wound healing, but its atherothrombotic role is a major focus of research.
  • The clinical significance of Lp(a) increases in diseases warrants further investigation, particularly concerning its contribution to atherothrombosis compared to genetically determined high levels.